Picture of Nykode Therapeutics ASA logo

NYKD — Nykode Therapeutics ASA News Story

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Brief: Nykode Therapeutics Announces Positive Final Results From Phase 2 VB-C-02 Trial

April 18 (Reuters) - Nykode Therapeutics ASA  NYKD.OL :
    * NYKODE THERAPEUTICS ANNOUNCES POSITIVE FINAL RESULTS FROM
ITS
PHASE 2 TRIAL OF VB10.16 IN COMBINATION WITH PD-L1 INHIBITOR
ATEZOLIZUMAB IN ADVANCED CERVICAL CANCER
    * VB10.16 WAS SAFE AND WELL TOLERATED IN COMBINATION WITH
ATEZOLIZUMAB
    * RESULTS SHOWED MEDIAN OVERALL SURVIVAL GREATER THAN 25
MONTHS
(NOT REACHED) AND 6.3 MONTHS MEDIAN PROGRESSION FREE SURVIVAL IN
PD-L1+ PATIENTS

Source text for Eikon:  ID:nObiryk6sa 
Further company coverage:  NYKD.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Nykode Therapeutics ASA

See all news